Merck & Co’s Carisma Therapeutics CARM Stock Holding History

Merck & Co’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.9K	Hold	1,473,240	–	–	0.01%	12
2025 Q4	$63.3K	Hold	1,473,240	–	–	0.02%	10
2025 Q3	$404K	Hold	1,473,240	–	–	0.18%	11
2025 Q2	$577K	Hold	1,473,240	–	–	0.27%	11
2025 Q1	$457K	Hold	1,473,240	–	–	0.28%	11
2024 Q4	$617K	Buy	+1,473,240	New	+$1.21M	0.24%	11

Other funds holding CARM

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

GSEP

Golden State Equity Partners South Coast Metro, California $37.1M AUM 20.75% 1-Year Est. Return

Merck & Co's CARM Position: Q1 2026 in Review

Merck & Co held its Carisma Therapeutics (CARM) position steady in Q1 2026 at 1,473,240 shares worth $47.9K. The position accounts for 0.01% of the portfolio, ranked #12.

Merck & Co first reported a position in CARM in Q4 2024 and has held it in 6 quarters since. The position peaked at $617K in Q4 2024. 3 funds tracked by Wall St. Rank hold CARM as of Q1 2026.

Merck & Co held 1,473,240 shares of Carisma Therapeutics worth $47.9K as of Q1 2026.
Merck & Co left its Carisma Therapeutics share count unchanged in Q1 2026.
Carisma Therapeutics made up 0.01% of Merck & Co's portfolio in Q1 2026, its #12 holding.
Merck & Co first reported a position in Carisma Therapeutics in Q4 2024 and has held it in 6 quarters since.
Merck & Co's Carisma Therapeutics position peaked at $617K in Q4 2024.
3 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.